ClinicalTrials.Veeva

Menu

Non-surgical Treatment of Peri-implant Mucositis

I

I.R.C.C.S Ospedale Galeazzi-Sant'Ambrogio

Status

Completed

Conditions

Peri-implant Mucositis

Treatments

Drug: Chlorhexidine
Device: Air-powder

Study type

Interventional

Funder types

Other

Identifiers

Details and patient eligibility

About

This a Randomized Controlled Clinical Trial comparing two techniques for the nonsurgical treatment of peri-implant mucositis. The main objective of the present randomized controlled clinical trial is to determine whether the application of a novel treatment strategy for peri-implant mucositis could lead to significantly improved clinical parameters as compared to standard treatment. Half of the patients receives treatment with manual instruments and chlorhexidine gel 1%, half receives treatment with submucosal biofilm removal by erythritol powder.

Enrollment

74 patients

Sex

All

Ages

35 to 65 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Subjects should have at least one implant (Renvert et al. 2009),
  • with bleeding on probing using a 0.2N probing force or spontaneous bleeding with local swelling (code 1, 2 or 3 as described in Corbella et al. 2011) and with bone resorption of no more of 1 mm (preferably no bone loss visible on radiographs) as evaluated through the use of standardized radiographs, taken with the use of an individualized radiograph holder in comparison with findings from radiographs taken immediately following placement of the implant prosthesis (similar to Renvert et al. 2009 and Algraffee et al. 2011).
  • females and males 35 to 65 years old; (IV) full mouth bleeding score % lower than 20%.

Exclusion criteria

  • systemic diseases that could affect the immune response or that could condition the bacterial colonization
  • use of anti-inflammatory prescription medications, or antibiotics within the preceding respectively 1 week and 3 months or during the study,
  • full-mouth plaque score (FMPS) >20%;
  • full-mouth bleeding score (FMBS) >20%,
  • smokers of more than 5 cigarettes a day,
  • Documented allergy or intolerance towards the components of the products used in the study,
  • Presence of active infection with suppuration.
  • Absence of periodontitis in the rest of the mouth
  • Pregnancy (certified by auto-declaration)
  • Patients suffering from upper respiratory tract infections, from chronic bronchitis
  • endocarditis, breast feeding, contagious disease, immune deficiency (neutropenia, angranulocytosis, diabetes, hemophilia), patients under treatment (radiotherapy, chemotherapy, antibiotics).

Trial design

Primary purpose

Treatment

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

Double Blind

74 participants in 2 patient groups

Standard treatment
Active Comparator group
Description:
Manual treatment One application of Chlorhexidine 1% gel
Treatment:
Drug: Chlorhexidine
Comprehensive treatment
Experimental group
Description:
Supragingival biofilm removal with Erythritol air-powder Submucosal biofilm removal with Erythritol air-powder (30%-60% power)
Treatment:
Device: Air-powder

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems